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Noroviruses (NoVs), a group of nonenveloped, single-stranded RNA viruses belonging to the Caliciviridae
family, are the leading cause worldwide of acute infectious gastroenteritis. Serious and eventual fatal
outcomes may be observed in at-risk populations such as the very young or older adults, especially in
those with underlying diseases. NoVs are highly infectious, with a low number of virus particles causing
infection, and they are highly resistant to environmental conditions. NoVs have multiple routes of
transmission including faecaleoral, aerosolized vomitus, person to person and via contaminated surfaces
or food and water. NoVs can cause frequent and dramatic outbreaks where people congregate in close
quarters such as hospitals, long-term care facilities, cruise liners and military barracks and ships. Of the
seven NoV genogroups, human disease is most frequently caused by genogroups I and II, although
genogroup IV has also been associated with illness. The absence of reliable, high-yield cell culture sys-
tems or animal models has steered the development of vaccines towards nonreplicating recombinant
capsid proteins including viruslike particles and the sub-virus-sized P particles. Takeda Vaccines is
developing a candidate NoV vaccine formulation based on adjuvanted viruslike particles from the GI.1
genotype and a consensus GII.4 sequence derived from three natural GII.4 variants. Early clinical trial
results show good tolerability and robust immune responses to both components. This approach is
designed to induce broad protective immune responses in adults and children. F. Baehner, CMI 2016;▪:1
© 2016 Takeda Pharmaceuticals International AG. Published by Elsevier Ltd on behalf of European Society
of Clinical Microbiology and Infectious Diseases. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Norovirus (NoV)-related disease regularly hits the news head-
lines, often as dramatic and repeated outbreaks aboard cruise ships
as well as in restaurants, schools, hospitals and institutions for care
of the elderly. However, the global sporadic disease burden in the
community is much more important than the headlines cases may
suggest. While still often underdiagnosed and underreported [1]
(http://www.who.int/foodsafety/publications/foodborne_disease/
fergreport/en/), NoV is the leading cause of acute gastroenteritis in
the world, especially in countries where vaccination against rota-
virus was successfully introduced [2e4].
Transmitted via the faecaleoral route, through contaminated
food or water or as aerosolized vomitus or fomites, NoV infection
typically results in acute nausea, uncontrolled and often projectile
vomiting and diarrhoea for up to 72 hours. Dehydration is the
greatest risk for complicated disease and may requireaceuticals International AG,
), Switzerland.
nal AG. Published by Elsevier Ltd on
e (http://creativecommons.org/lice
et al., Vaccines against norovi
16/j.cmi.2015.12.023hospitalization for intravenous ﬂuid therapy. While in developing
countries most of the severe disease burden is in the very young; in
industrialized countries a substantial part of the NoV-related
morbidity and mortality occurs in older adults [5,6]. Older adults,
young children and immunocompromised individuals may expe-
rience prolonged clinical disease and virus shedding. Patients with
underlying conditions such as chronic renal or chronic cardiac
disease may have poor outcomes after a NoV gastroenteritis
episode [7]. Only 5e10% of individuals with symptoms seek med-
ical attention, and in the United Kingdom it is estimated that there
are about 300 additional cases in the community for each case
reported to the national health authority [1]. Not surprisingly this
disease burden also results in signiﬁcant direct (medical) and in-
direct (societal) healthcare costs: an estimated $5.5 billion in the
United States, as well as economic costs due to work loss [8,9].
The ﬁrst identiﬁcation of the causative agent was from an
outbreak of “winter vomiting disease” in Norwalk, Ohio (1968) [10].
The later visualization by Kapikian et al. [11] and then the genetic
characterization of the pathogen in the 1990s allowed for its clas-
siﬁcation as a member of the Caliciviridae family [12]. They arebehalf of European Society of Clinical Microbiology and Infectious Diseases. This is
nses/by-nc-nd/4.0/).
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into seven genogroups (GI to GVII) and further subdivided into
genotypes. GI and GII NoVs are the genogroups primarily respon-
sible for human illness, although GIV has also been detected in
humans [13]. Natural immunity after NoV exposure appears to be
strain or genotype speciﬁc, with little or no protection conferred
across genogroups, and the duration of natural immunity has been
estimated to range 4e9 years [14]. Genogroup II type 4 (GII.4)
currently accounts for approximately 60e90% of all NoV outbreaks,
making it the dominant type worldwide [15]. This genotype has
been shown to undergo genetic evolution, and new GII.4 strains
emerge every 2e4 years. RNA recombination is one of the major
driving forces of virus evolution and has been identiﬁed for a
number of different genotypes, including GII.4 [16]. NoVs undergo
genetic evolution, and new genotypes and subtypes emerge every
2e4 years with limited natural cross-protection between gen-
ogroups. In 2012 a new GII.4 strain emerged (Sydney), and recent
data show increased numbers of GII.17 cases in Asia [17].
As a “perfect human pathogen” [5] that is difﬁcult to avoid, that
is highly infectious and for which there is no etiologic treatment,
NoV represents a good candidate for potential prevention through
vaccination. A serologic correlate of protection against NoV infec-
tion or disease has not been deﬁnitively established, and assess-
ment of neutralizing activity is not possible because of the lack of an
in vitro culture model for NoV. However, since NoVs most likely
initiate infection by attachment to human histoeblood group an-
tigens (HBGAs) [18], assessment of the ability to block this inter-
action may be a surrogate for neutralizing activity and has been
identiﬁed as a potential serologic correlate of protection in human
challenge studies [19].
The search for NoV vaccines has been hampered by the absence
of reliable, efﬁcient systems to propagate the virus and the paucity
of small animal models to study (vaccine-induced) protective re-
sponses. Therefore, one focus has been on expression systems for
nonreplicating recombinant proteins either as viruslike particles
(VLPs) or a P particle. NoVs are covered by a protein capsid that is
formed by a major (VP1) and a minor (VP2) structural protein. The
major capsid protein VP1, when expressed in cell culture, assembles
spontaneously into 180-unit VLPs that are morphologically and
antigenically similar to native virus capsids [20]. VLPs can be
expressed in systems such as recombinant viral vectors (e.g.
baculovirus, Venezuelan equine encephalitis virus, vesicular sto-
matitis virus) insect cells, mammalian cells, plasmids, and yeast as
well as in transgenic plants (tomato, potato, tobacco). The NoV P
particle is an octahedral sub-virus-sized nanoparticle formed by 24
copies of the protrusion (P) domain of the NoV capsid protein [21].
P particles can be produced in Escherichia coli and are very stable
and strongly immunogenic.
Vaccine Candidates
Several NoV vaccine candidates have been evaluated in pre-
clinical trials, including bivalent and trivalent VLPs, and truncated
VP1 P particles from the Universities of Arizona, Tampere and the
Cincinnati Children’s Hospital Medical Center, respectively.
Following from early work conducted with orally administered VLP
antigens [22e25], Velasquez et al. [26] from Arizona State Univer-
sity, in an attempt to improve the immunogenicity of a bivalent
NoV VLP GI.1, GII.4 formulation for intranasal use, were able to
demonstrate robust systemic and mucosal immunity in various lab
animals with a mucoadhesive (GelSite)-based preparation [27].
Tamminen et al. [28] from the University of Tampere used an
intramuscular combined vaccine candidate consisting of a bivalent
NoV (GI.3, GII.4) component with a rotavirus (rVP6) component in
BALB/c mice to show high-level vaccine-type-speciﬁc serum andPlease cite this article in press as: Baehner F, et al., Vaccines against norovi
and Infection (2016), http://dx.doi.org/10.1016/j.cmi.2015.12.023intestinal immunoglobulin G (IgG) as well as cross-reactive IgG
antibodies against heterologous NoV VLPs (GII.4, GII.12, GI.1). Fang
et al. [29] from the Cincinnati Children's Hospital were able to show
that NoV P domain complexes injected intramuscularly in BALB/c
mice were efﬁciently presented by dendritic cells to elicit humoral
and cellular immune responses. Chimeras with both the NoV P
particle and the rotavirus VP-8 may serve as a future dual vaccine
against both pathogens.
The VLP-based approach from Takeda Vaccines, using a baculo-
virus/insect cell expression system, has resulted in several investi-
gational intramuscular aluminium hydroxide (Al(OH)3)-based
vaccine formulations being pursued,which are currently undergoing
testing in clinical trials. Thevaccinecandidates are designed to elicit a
high antibody response to both the component GI.1 and GII.4 anti-
gens, representing the two major genogroups infecting humans, as
well as broad cross-protective responses against other genotypes.
The GI.1 component is based on the prototypic Norwalk virus, while
the GII.4 component is based on a consensus sequence between
three GII.4 viruses: 2006a (Yerseke), 2006b (Den Haag) and 2002
(Houston) [30]. Initial preclinical studies in animals had shown that
this consensus GII.4 VLP elicits a broad antibody response against
multipleGII.4 strains isolated over years of antigendrift [29]. Proof of
concept was demonstrated in humans using an early formulation
administered intranasally [31], but subsequent formulations devel-
oped for intramuscular injection have been associated with higher
seroresponse rates after administration of fewer doses.
Takeda Vaccines Candidate Studies
Candidate intramuscular vaccine formulations with doses
ranging 5e150 mg of each of the two VLPs, with and without 3-O-
desacyl-40-monophosphoryl lipid A (MPL; GlaxoSmithKline) as an
adjuvant in addition to Al(OH)3, have been evaluated in phase 1 and
2 trials in adults [32,33]. All formulations were generally well
tolerated with acceptable safety proﬁles, but as expected with an
MPL-adjuvanted vaccine, there were higher rates of pain (46.8% vs.
12.9%) and tenderness (66.1% vs. 24.2%) at the injection site in the
vaccine subjects compared to the placebo subjects. These injection-
site reactions resolved quickly. Data on all other solicited events
(systemic or local) suggested no difference between these two
groups.
Robust and high immune responses to the vaccine GI.1 VLP and
GII.4 cVLP have been observed when assessed as total Ig, IgG and
IgA, and functional antibody responses as measured by the ability
to block binding to HBGA, the purported ligand for NoV attachment
[32e34].
In a double-blind, randomized, placebo-controlled phase 1
study, Treanor et al. [32] evaluated escalating VLP doses (5, 15, 50
and 150 mg of each VLP) in different age strata of healthy adults aged
18e85 years. Vaccinees received two intramuscular doses 28 days
apart. All formulations were well tolerated with no dose-related
effects or increased reactogenicity after the second dose. Solicited
adverse events were primarily mild or moderate in severity, with
headache the most frequent systemic, and tenderness and pain the
most frequent local adverse events. Serum immune responses
(total Ig, IgG and IgA) to each of the vaccine VLPs peaked at day 7
after the ﬁrst dose with no evidence of boosting after the second
dose. It should be noted, however, that all of these adult subjects
had preexisting anti-NoV serum antibodies at baseline, indicating
that they had probably been primed by earlier natural exposure.
Responses were similar by age group. Interestingly, the highest
immune responses were observed for the GI.1 VLP antigen in the
150/150 mg dose, whereas the highest immune responses to the
GII.4 VLP antigen were observed with the 50/50 mg dose. The 50/
50 mg vaccine was therefore selected for further evaluation in therus: state of the art trials in children and adults, Clinical Microbiology
Table 1
Clinical efﬁcacy against oral virus challengea
Gastroenteritis symptom Vaccinated (n¼ 50) Placebo (n¼ 48) Rate difference (95% CI) % Reduction (95% CI) p (Fisher’s exact test)
Per-protocol analyses (RT-PCR conﬁrmation of infection)
NoV infected 27 (54%) 30 (62.5%) 13.6 (21.0, 38.3) d 0.420
NoV infected and ill 13 (26%) 16 (33.3%) 22.0 (44.3, 57.8) d 0.509
Post hoc analyses independent of laboratory ascertainment
Severe vomiting and/or diarrhoea 0 (0%) 4 (8.3%) 8.3 (16.2, 0.5) 100% 0.054
Moderate or severe vomiting and/or diarrhoea 3 (6.0%) 9 (18.8%) 12.8 (25.6, 0.1) 68% (11.2, 90.8) 0.068
Mild, moderate or severe vomiting and/or diarrhoea 10 (20%) 20 (41.7%) 21.7 (39.5, 3.8) 52% (8.3, 74.9) 0.028
CI, conﬁdence interval; NoV, norovirus; RT-PCR, reverse transcription PCR.
a Per protocol population deﬁned by RT-PCR-conﬁrmed infection and post hoc analyses independent of laboratory ascertainment) [34].
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against various heterologous strains within both genogroups and
genotypes, including the GII.4 Sydney 2012 strain, which only
emerged 1e2 years after the trial [34]. A serologic correlate of
protection against NoV infection or disease has not been deﬁni-
tively established, and assessment of neutralizing activity is not
possible because of the lack of an in vitro culture model for NoV.
As already noted, NoVs most likely initiate infection by attach-
ment to human HBGAs [18], so assessment of the ability to block
this interaction may be a surrogate for neutralizing activity. In the
challenge model, serum HBGA-blocking antibody titres have been
associated with signiﬁcant protection against NoV-induced infec-
tion and illness symptoms [19]. The achievement of this titre in the
majority of subjects in each age group suggests that intramuscular
delivery may be a promising route of administration for NoV vac-
cines. Bernstein et al. [33] published the results from a randomized,
double-blind challenge study in healthy adults aged 18e50 years in
the United States. Efﬁcacy wasmeasured versus placebo in 98 study
participants in the per-protocol population, who received two
doses of either the Takeda Vaccines candidate NoV vaccine (50 mg of
each VLP with MPL and Al(OH)3) or saline placebo 28 days apart.
Challenge was approximately 1 month after the second dose with
oral administration of live GII.4eFarmington Hill variant, a different
strain from the vaccine strain, similar to season-to-season strain
variability. Using the predeﬁned deﬁnitions of NoV gastroenteritis,
based on the number of episodes and volume of diarrhoea and
vomitus as well as selected symptoms, the vaccine did not signiﬁ-
cantly reduce the incidence of protocol-deﬁned illness. The primary
endpoint of the study was not met, primarily due to a lower attack
rate than expected in the placebo group (possibly due to more
recent natural exposure to GII.4 viruses), and that reverse tran-
scription PCR conﬁrmation does not differentiate illness from
infection. However, the study met a secondary endpoint when
using the modiﬁed Vesikari score, reducing the severity of disease
from 7.3 to 4.5 (p¼0.002). Consistent with other vaccines (e.g.
rotavirus vaccines), the NoV vaccine was also found to be more
protective against severe forms of acute gastroenteritis than against
mild disease (Table 1). Faecal shedding of challenge virus peaked on
days 3e4 after challenge. After infection, the quantity of virus was
higher in those who became ill compared to those who remained
asymptomatic according to protocol deﬁnitions (p¼0.005).Conclusions
In conclusion, recombinant technology, including the expres-
sion of VLPs and P domain complexes of NoVs, has allowed for the
development of promising NoV candidate vaccines. Because of the
genetic and antigenic diversity of NoVs and the periodic emergence
of new variants, a bivalent vaccine approach representing themajor
antigenic NoV types seems warranted for adequate broad strain
coverage.Please cite this article in press as: Baehner F, et al., Vaccines against norovi
and Infection (2016), http://dx.doi.org/10.1016/j.cmi.2015.12.023The ﬁrst VLP candidate vaccine formulations derived from the
prototype Norwalk agent and the dominant GII.4 genotype are in
phase 2 clinical trials, with promising safety and immunogenicity,
while a number of other VLP and P domain complexebased vac-
cines are following in preclinical stages. The substantial disease
burden and costs associated with NoV can potentially be reduced
through vaccination, provided the early indications of clinically
meaningful protection and cross-functional antibody responses are
conﬁrmed in the planned larger-scale efﬁcacy trials.
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